Abstract
Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thrombembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade’s classic anticoagulants like heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists have been the gold standards in therapy and are widely used. Novel oral anticoagulants (NOAC) like the direct thrombin inhibitor (dabigatran etexilate) and the direct factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) have been introduced to overcome the drawbacks of vitamin K antagonists. The efficacy and safety of these NOAC have been investigated in several randomized trials. Here we want to give an overview about the NOACS in the treatment of acute and chronic VTE and their use for primary prevention of acute VTE.
Keywords: Coumadin, deep vein thrombosis, NOAC, thrombembolism, thrombotic prophylaxsis, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis
Volume: 15 Issue: 2
Author(s): Muharrem Akin, Andreas Schäfer, Ibrahim Akin, Julian Widder and Michael Brehm
Affiliation:
Keywords: Coumadin, deep vein thrombosis, NOAC, thrombembolism, thrombotic prophylaxsis, warfarin.
Abstract: Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thrombembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade’s classic anticoagulants like heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists have been the gold standards in therapy and are widely used. Novel oral anticoagulants (NOAC) like the direct thrombin inhibitor (dabigatran etexilate) and the direct factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) have been introduced to overcome the drawbacks of vitamin K antagonists. The efficacy and safety of these NOAC have been investigated in several randomized trials. Here we want to give an overview about the NOACS in the treatment of acute and chronic VTE and their use for primary prevention of acute VTE.
Export Options
About this article
Cite this article as:
Akin Muharrem, Schäfer Andreas, Akin Ibrahim, Widder Julian and Brehm Michael, Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209110620
DOI https://dx.doi.org/10.2174/1871529X1502151209110620 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Flow-Independent Exhaled Nitric Oxide Parameters in the Assessment of Airway Diseases
Current Topics in Medicinal Chemistry Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Overexpression of a Modified Amaranth Protein in Escherichia coli with Minimal Media and Lactose as Inducer
Recent Patents on Biotechnology Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis
Current Vascular Pharmacology Fatal Lactic Acidosis Precipitated by Nifedipine in a Patient Treated with Disulfiram and Antiretrovirals
Drug Metabolism Letters Dimethyl Sulfoxide as an Excitatory Modulator and its Possible Role in Cancer Pain Management
Inflammation & Allergy - Drug Targets (Discontinued) Mediterranean Diet And Longevity: An Example Of Nutraceuticals?
Current Vascular Pharmacology Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Neurochemicals Involved in Medullary Control of Common Carotid Blood Flow
Current Neuropharmacology Management of Osteoporosis: Seeing the Future
Medicinal Chemistry Reviews - Online (Discontinued) Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Structural Features of Angiotensin-I Converting Enzyme Catalytic Sites: Conformational Studies in Solution, Homology Models and Comparison with Other Zinc Metallopeptidases
Current Topics in Medicinal Chemistry A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities
Current Drug Targets Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Drugs in Pediatric Ischemic Stroke
Current Drug Targets Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design